Hung and colleagues recently demonstrated that hRNase5/ANG functions as a ligand of EGFR and a serum biomarker to predict EGFR-TKI erlotinib response in patients with pancreatic adenocarcinoma [46]. The gene discussed is EGFR; the disease is pancreatic adenocarcinoma.